AS: Tapering Therapy

Lower Tx Dose in Ankylosing Spondylitis Possible

Image result for tapering anti-tnf in as

Dose reduction may mean substantial savings with minimal clinical risk

Long-term TNFi tapering possible for some with ankylosing spondylitis

BIRMINGHAM, ENGLAND – A proportion of patients with ankylosing spondylitis (AS) were able to remain on a reduced-dose regimen of a tumor necrosis factor inhibitor (TNFi) for almost 4 years, according to data from a small study presented at the British Society for Rheumatology annual confer…